Skip to main content
. 2016 Feb 17;7(16):21496–21509. doi: 10.18632/oncotarget.7452

Figure 5. Combination therapy supra-additively enhanced the fibrosarcoma growth inhibition and delay in mouse model.

Figure 5

A. S3I-201 induced significant tumour growth inhibition and delay in orthotopic fibrosarcoma xenografted nude mice. 0.1 × 106 HT1080 cells were injected intramuscularly into the right posterior thigh musculature of each nude mouse. On 24 hours post inoculation of tumour cells, all mice started treatment with vehicle, 2.5 or 5 mg/kg S3I-201 via intraperitoneal injection once daily. N = 3-4 B. Gefitinib (up to 20 mg/kg) did not induce tumour growth inhibition in orthotopic fibrosarcoma xenografted nude mice. N = 5 C. Combination therapy synergistically enhanced the fibrosarcoma growth inhibition. N = 8 D. Kaplan-Meier survival curve of human fibrosarcoma xenografted mice comparing single or combination therapy. The difference was significant (log-rank test). N = 8.